Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 51.2% in April

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 7,266 shares, a drop of 51.2% from the April 15th total of 14,880 shares. Based on an average trading volume of 16,053 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC boosted its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned about 7.80% of Xenetic Biosciences worth $387,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 15.12% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Xenetic Biosciences Price Performance

XBIO opened at $3.04 on Monday. The stock’s fifty day moving average is $3.02 and its two-hundred day moving average is $2.63. The company has a market capitalization of $6.96 million, a P/E ratio of -2.53 and a beta of 2.20. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter. The firm had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.